Kliniken & Institute … Kliniken Chirurgische Klinik… Allgemein-, Viszeral-… Forschung Chirurgische Forschung … AG Molekulare… Publikationen Ausgewählte…

10 ausgewählte Publikationen aus 114 peer-review Manuskripten

10 Ausgewählte Publikationen aus 145 peer-review Manuskripten:

1. Nwaeburu CC, Abukiwan A, Zhao Z, Herr I (2017). Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer. Molecular Cancer 16:23. IF2020 27.401


2. Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW,Moldenhauer G, Herr I. (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin Cancer Res, 18:1028. IF2020 12.531


3. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov A, Herr I. (2010). Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res, 70:5004. IF202012.701


4.  Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov AV, Herr I(2009). Sulforaphane targets pancreatic tumor-initiating cells by NF-kB-induced anti-apoptotic signaling. GUT, 58:949. IF2020 23.059


5. Herr I, Schemmer P and Büchler MW. (2007). On the TRAIL to therapeutic intervention in liver disease. Hepatology 46:266. IF2020 17.425


6. Herr I and Pfitzenmaier J (2006). Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7:425IF2020 41.316


7. Wenger T, Mattern J, Penzel R, Gassler N, Haas T, Sprick M, Walczak H, Krammer PH, Debatin K-M and Herr I (2006). Specific resistance uponlentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ 13:1740. IF2020 10.717


8. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer, PH, Knebel-Döberitz M and Debatin K-M (2003). Glucocorticoid co-treatment induces apoptosis resistance towards cancer therapy in carcinomas. Cancer Res 63:3112. IF2020 12.701


9. Herr I, Wilhelm D, Boehler T, Angel P and Debatin K-M (1997). Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.  EMBO J 16:6200. IF2020 11.598


10. Friesen C*, Herr I* (*equal contribution), Krammer P and Debatin K-M (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis of leukemia cells.Nature Med 2: 574. IF2020 53.44